These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38506327)

  • 1. Molecular basis for differential recognition of an allosteric inhibitor by receptor tyrosine kinases.
    Verma J; Vashisth H
    Proteins; 2024 Aug; 92(8):905-922. PubMed ID: 38506327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Models for a Series of Allosteric Inhibitors of IGF1R Kinase.
    Verma J; Vashisth H
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Models for a Series of Allosteric Inhibitors of IGF1R Kinase.
    Verma J; Vashisth H
    bioRxiv; 2024 May; ():. PubMed ID: 38617226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidating specificity of an allosteric inhibitor WNK476 among With-No-Lysine kinase isoforms using molecular dynamic simulations.
    Amarnath Jonniya N; Sk MF; Kar P
    Chem Biol Drug Des; 2021 Sep; 98(3):405-420. PubMed ID: 33969941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of insulin-like growth factor I receptor tyrosine kinase by ethanol.
    Rubin R; Harrison R; Chen XF; Corzitotto J; Hoek JB; Hallak H
    Biochem Pharmacol; 2004 Nov; 68(10):2009-17. PubMed ID: 15476672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insight into the structural mechanism for PKBα allosteric inhibition by molecular dynamics simulations and free energy calculations.
    Chen SF; Cao Y; Han S; Chen JZ
    J Mol Graph Model; 2014 Mar; 48():36-46. PubMed ID: 24374242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational insights into allosteric inhibition of focal adhesion kinase: A combined pharmacophore modeling and molecular dynamics approach.
    Kumar V; Singh P; Parate S; Singh R; Ro HS; Song KS; Lee KW; Park YM
    J Mol Graph Model; 2024 Jul; 130():108789. PubMed ID: 38718434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
    Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
    J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
    Pandey P; Roy KK; Doerksen RJ
    J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions.
    James KA; Verkhivker GM
    PLoS One; 2014; 9(11):e113488. PubMed ID: 25427151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK.
    Kong X; Sun H; Pan P; Zhu F; Chang S; Xu L; Li Y; Hou T
    Phys Chem Chem Phys; 2018 Feb; 20(7):4851-4863. PubMed ID: 29383359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states.
    Lake EW; Muretta JM; Thompson AR; Rasmussen DM; Majumdar A; Faber EB; Ruff EF; Thomas DD; Levinson NM
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11894-E11903. PubMed ID: 30518564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding and discerning interactions of PTP1B allosteric inhibitors: novel insights from molecular dynamics simulations.
    Shinde RN; Sobhia ME
    J Mol Graph Model; 2013 Sep; 45():98-110. PubMed ID: 24012873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases.
    Bell IM; Stirdivant SM; Ahern J; Culberson JC; Darke PL; Dinsmore CJ; Drakas RA; Gallicchio SN; Graham SL; Heimbrook DC; Hall DL; Hua J; Kett NR; Kim AS; Kornienko M; Kuo LC; Munshi SK; Quigley AG; Reid JC; Trotter BW; Waxman LH; Williams TM; Zartman CB
    Biochemistry; 2005 Jul; 44(27):9430-40. PubMed ID: 15996097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
    Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
    J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.
    Zhang J; Ji T
    J Mol Model; 2017 Jan; 23(1):1. PubMed ID: 27921184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
    Yang Y; Shen Y; Liu H; Yao X
    J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into the Binding of DFG-out Allosteric Inhibitors to B-Raf Kinase Using Molecular Dynamics and Free Energy Calculations.
    Coronel L; Granadino-Roldán JM; Pinto M; Tomas MS; Pujol MD; Rubio-Martinez J
    Curr Comput Aided Drug Des; 2015; 11(2):124-36. PubMed ID: 26135342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK.
    Tian Y; Yu Y; Shen Y; Wan H; Chang S; Zhang T; Wan S; Zhang J
    J Chem Inf Model; 2017 Apr; 57(4):977-987. PubMed ID: 28318251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.